DRUG NAME: Cefprozil

1. More predictable and higher oral bioavailability (~95% vs ~37–52% for cefuroxime axetil)
2. No food dependency for absorption (cefuroxime axetil MUST be taken with food; cefprozil can be taken with or without food)
3. Better taste in suspension (no bitter ester moiety — a critical advantage in paediatric prescribing)

• Paediatric practice — where its excellent palatability (pleasant-tasting suspension) gives it a significant advantage over the notoriously bitter cefuroxime axetil suspension
• Outpatient respiratory infections — where its food-independent, high oral bioavailability provides reliable serum levels without the “take with food” dependency of cefuroxime axetil
• Antimicrobial stewardship — as a narrower-spectrum alternative to third-generation oral cephalosporins (cefixime, cefpodoxime) for community-acquired upper and lower respiratory infections

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Oral (film-coated tablets and powder for oral suspension only)

---

Biosimilar Status:

---

Formulations Available in India

A. Film-Coated Tablets (Cefprozil Monohydrate)

B. Powder for Oral Suspension (Dry Syrup) — Cefprozil Monohydrate

• Young children (6 months to 4 years) who cannot swallow tablets
• Children who have previously refused cefuroxime axetil suspension
• Caregivers who have difficulty administering bitter-tasting medications

C. Fixed-Dose Combinations (FDCs)

D. Formulations NOT Available

---

PHARMACOKINETICS

Primary PK Table — Oral Route

Prodrug Status

• Cefuroxime axetil — a prodrug requiring intestinal esterase hydrolysis
• Cefpodoxime proxetil — a prodrug requiring esterase hydrolysis
• Cefditoren pivoxil — a prodrug

Non-Linear PK

---

Comparative Pharmacokinetic Table: Cefprozil vs Other Oral Cephalosporins Available in India

---

Key Clinical PK Distinctions of Cefprozil

• Paediatric respiratory infections (AOM, pharyngitis, sinusitis) are extremely common
• Oral antibiotics are the mainstay of treatment
• Compliance depends heavily on taste acceptance
• Caregivers frequently abandon courses of bitter-tasting antibiotics
  …a well-tasting second-generation cephalosporin fills a genuine clinical need.

---

Spectrum of Activity

---

Population Pharmacokinetic Notes

---

Cefprozil vs Amoxicillin-Clavulanate — The Primary Comparator for Most Shared Indications

• For most outpatient respiratory infections: Amoxicillin-clavulanate remains first-line per Indian guidelines (API Textbook, ICMR, IAP). Cefprozil is a valid alternative when amoxicillin-clavulanate fails, is not tolerated (especially GI intolerance), or in patients with non-severe penicillin allergy.
• For paediatric AOM/sinusitis where taste determines compliance: Cefprozil suspension may achieve better treatment completion than cefuroxime axetil suspension due to dramatically superior palatability — potentially justifying its higher cost if the child has refused or vomited cefuroxime.
• If anaerobic coverage is needed (aspiration, bite wounds, dental infections): → Amoxicillin-clavulanate is preferred (or add metronidazole to cefprozil).
• If GI tolerability is a priority (history of antibiotic-associated diarrhoea, elderly): → Cefprozil has lower diarrhoea rates than amoxicillin-clavulanate.
• If food intake is unreliable (ill, elderly, fasting patients): → Cefprozil (food-independent absorption) is preferable over cefuroxime axetil or amoxicillin-clavulanate.

---

ADULT INDICATIONS + DOSING

---

⚠️ ANTIMICROBIAL STEWARDSHIP NOTES FOR CEFPROZIL IN INDIA

• First-line amoxicillin/amoxicillin-clavulanate has failed (no improvement at 48–72 hours)
• Patient cannot tolerate amoxicillin-clavulanate (GI intolerance — especially diarrhoea)
• Non-severe penicillin allergy (where cephalosporins can be used with ~2–5% cross-reactivity)
• Paediatric taste compliance is a barrier (see Part 3)

• ⛔ MRSA infections — no activity
• ⛔ ESBL-producing gram-negative infections — no activity (high prevalence in India)
• ⛔ Pseudomonas infections — no activity
• ⛔ Gonorrhoea — resistance too high; use ceftriaxone per NACO/ICMR
• ⛔ Meningitis — poor CSF penetration even with inflamed meninges
• ⛔ Enterococcal infections — intrinsic resistance
• ⛔ Anaerobic infections (aspiration pneumonia, intra-abdominal, dental abscess) — no B. fragilis coverage; use amoxicillin-clavulanate, ampicillin-sulbactam, or add metronidazole
• ⛔ Serious/systemic infections requiring parenteral therapy — cefprozil has NO IV formulation
• ⛔ Atypical pneumonia as monotherapy — no activity against Mycoplasma, Chlamydophila, Legionella

---

GENERAL ADULT DOSING REFERENCE TABLE

• Starting dose: Full therapeutic dose from first administration (no loading dose; no titration for antibiotics)
• Titration: Not applicable
• Usual maintenance dose: 250–500 mg oral q12h (indication-dependent)
• Maximum dose: Max 500 mg per dose; Max 1 g per day

---

Primary Indications (Approved / Standard in India)

---

Indication 1: PHARYNGOTONSILLITIS — Group A Streptococcal (GAS)

1. When to prefer cefprozil over alternatives:
2. • ✅ When a convenient once-daily oral cephalosporin is desired for GAS pharyngitis (alternatives requiring more frequent dosing: penicillin V — TDS-QDS; amoxicillin — BID-TDS; cephalexin — TDS-QID)
   • ✅ When patient has non-severe penicillin allergy (non-anaphylactic) — cephalosporins can be used with ~2–5% cross-reactivity rate
   • ✅ When recurrent GAS pharyngitis is suspected to involve co-pathogen beta-lactamase-producing organisms (theoretical shielding effect) — some experts advocate cephalosporins over penicillin for recurrent GAS pharyngitis (API Textbook, Indian practice)
   • ✅ Paediatric cases where taste determines compliance (cefprozil suspension is well-accepted — see Part 3)
3. When NOT to use:
4. • ⛔ NOT first-line for initial episode of uncomplicated GAS pharyngitis — first-line remains penicillin V (cheapest, narrowest spectrum, decades of proven efficacy for rheumatic fever prevention) or amoxicillin (better taste, once-daily or BID dosing). IAP Guidelines and API Textbook list penicillin/amoxicillin as first-line.
   • ⛔ NOT for peritonsillar abscess or complicated pharyngitis (requires parenteral therapy + drainage)
   • ⛔ NOT for viral pharyngitis — ⚠️ confirm GAS by rapid antigen detection test (RADT) or throat culture before prescribing. In Indian practice, clinical scoring (modified Centor/McIsaac score ≥3) may be used when RADT is unavailable.
   • ⛔ NOT in severe/anaphylactic penicillin allergy — use azithromycin or clindamycin instead
5. NLEM India status: ❌ Cefprozil is NOT listed in NLEM India 2022. For GAS pharyngitis, NLEM-listed first-line options are: amoxicillin, phenoxymethylpenicillin (penicillin V), benzathine penicillin G (IM).
6. Time to expected clinical response: Symptom improvement (reduced sore throat, defervescence) typically within 24–48 hours. If no improvement by 72 hours → reassess diagnosis (viral? peritonsillar abscess? mononucleosis?), consider throat culture if not already done, and evaluate alternative antibiotic.
7. Criteria for treatment failure and switching:
8. • Persistent symptoms at 72 hours despite compliance
   • Microbiological failure (persistent positive GAS culture after full course — check only if clinically indicated)
   • Recurrent GAS pharyngitis within 4 weeks of completing therapy
   • Switching options: Amoxicillin-clavulanate (for possible beta-lactamase co-pathogen shielding), clindamycin (for penicillin-allergic patients or treatment failures), azithromycin (for penicillin allergy)
9. Mandatory baseline investigations:
10. • RECOMMENDED: Rapid antigen detection test (RADT) for GAS, or throat culture. Clinical diagnosis alone is acceptable in resource-limited settings when McIsaac score ≥3, but microbiological confirmation is preferred.
    • Not required: CBC, CRP, renal function (for a standard 10-day outpatient course in a young, otherwise healthy patient)
11. Specialist initiation: Not required — primary care appropriate. Refer to ENT if: recurrent pharyngitis (>6 episodes/year), peritonsillar abscess, suspected malignancy, or surgical consideration (tonsillectomy).
12. Indian guideline source: API Textbook of Medicine — Pharyngitis chapter (lists cephalosporins as second-line); IAP Guidelines on GAS Pharyngitis (recommend penicillin/amoxicillin as first-line; cephalosporins as second-line alternative); ICMR AMR Guidelines 2019.
13. Key disease-specific safety warning:
    ⚠️ India has one of the world’s highest burdens of rheumatic heart disease (RHD). Complete 10-day eradication therapy for confirmed GAS pharyngitis is CRITICAL for primary prevention of acute rheumatic fever. Do NOT prescribe shorter courses (3-day, 5-day) with cefprozil for GAS pharyngitis — despite studies in other contexts suggesting shorter cephalosporin courses for GAS, the risk of rheumatic fever in the Indian population mandates full 10-day treatment. ⛔ Never use “symptom resolution” as the endpoint — the goal is microbiological eradication, which requires 10 days.
14. Common dose adjustment scenarios: Renal impairment — adjust if CrCl <30 mL/min (see Renal Adjustment, Part 3). No hepatic adjustment. Elderly — check CrCl before prescribing.

---

Indication 2: ACUTE OTITIS MEDIA (AOM) — Second-Line Therapy

1. When to prefer cefprozil for AOM:
2. • ✅ Second-line after amoxicillin failure (no improvement at 48–72 hours on high-dose amoxicillin 80–90 mg/kg/day). API Textbook and IAP Guidelines list cephalosporins (cefprozil, cefuroxime axetil) or amoxicillin-clavulanate as second-line for AOM.
   • ✅ When amoxicillin is contraindicated (non-severe penicillin allergy)
   • ✅ When beta-lactamase-producing H. influenzae is suspected (recurrent AOM, daycare attendance, recent amoxicillin exposure within past 30 days)
   • ✅ Paediatric palatability advantage — cefprozil suspension taste is dramatically better than cefuroxime axetil (see Part 3)
3. When NOT to use:
4. • ⛔ NOT first-line — first-line is high-dose amoxicillin (80–90 mg/kg/day in children; 500–1000 mg q8h in adults) per IAP, AAP, and API guidelines
   • ⛔ NOT for complicated AOM (mastoiditis, intracranial extension) — requires IV antibiotics + ENT referral
   • ⛔ NOT for chronic suppurative otitis media (CSOM) — different microbiology, requires topical + systemic treatment
5. NLEM India: ❌ Not listed. Amoxicillin is NLEM-listed as the first-line AOM agent.
6. Time to expected clinical response: Symptom improvement (reduced ear pain, defervescence) within 48–72 hours. If no improvement → ENT referral for tympanocentesis and culture.
7. Treatment failure criteria: Persistent symptoms at 72 hours, worsening despite therapy, development of complications (mastoiditis, facial nerve palsy). Consider tympanocentesis for culture-guided therapy.
8. Mandatory baseline investigations:RECOMMENDED: Otoscopic examination (pneumatic otoscopy if available — confirmatory). No laboratory investigations required for uncomplicated AOM.
9. Specialist initiation: Not required for uncomplicated AOM — primary care appropriate.
10. Indian guideline source: IAP Guidelines on AOM; API Textbook — ENT Infections chapter; ICMR AMR Guidelines 2019.
11. Key safety warning: ℹ️ AOM in children <6 months or AOM with complications at any age: specialist referral mandatory. Do NOT manage with oral antibiotics alone.
12. Dose adjustment: Renal impairment — adjust if CrCl <30 mL/min. No hepatic adjustment.

---

Indication 3: ACUTE BACTERIAL SINUSITIS (ABS) — Second-Line Therapy

1. When to prefer cefprozil:
2. • ✅ Second-line after amoxicillin or amoxicillin-clavulanate failure/intolerance
   • ✅ Non-severe penicillin allergy
   • ✅ GI intolerance to amoxicillin-clavulanate (lower diarrhoea rate with cefprozil)
   • Covers the three primary ABS pathogens: S. pneumoniae, H. influenzae (including beta-lactamase producers), M. catarrhalis
3. When NOT to use:
4. • ⛔ NOT first-line — first-line is amoxicillin or amoxicillin-clavulanate per API Textbook and ICMR guidelines
   • ⛔ NOT for complicated sinusitis with orbital or intracranial extension — requires IV antibiotics + CT imaging + ENT/neurosurgery referral
   • ⛔ NOT for fungal sinusitis (allergic fungal sinusitis, invasive fungal sinusitis — different aetiology)
   • ⛔ NOT for nosocomial sinusitis (ICU patients with nasogastric/endotracheal tubes — likely MDR organisms)
5. Diagnosis confirmation: Bacterial sinusitis requires ≥1 of: symptoms ≥10 days without improvement, worsening after initial improvement (“double sickening”), or severe onset (fever ≥39°C + purulent nasal discharge ≥3 consecutive days). ⚠️ Do NOT prescribe antibiotics for viral rhinosinusitis (the vast majority of cases presenting in Indian primary care).
6. NLEM India: ❌ Not listed. Amoxicillin-clavulanate is NLEM-listed for this indication.
7. Time to expected clinical response: Symptom improvement within 48–72 hours. If no improvement by day 3–5 → reassess diagnosis, consider imaging (CT paranasal sinuses), ENT referral.
8. Baseline investigations:OPTIONAL: CT PNS if complicated or recurrent. No routine laboratory investigations for uncomplicated ABS.
9. Specialist initiation: Not required for uncomplicated ABS — primary care appropriate.
10. Indian guideline source: API Textbook — Sinusitis chapter; ICMR AMR Guidelines 2019; ENT India consensus guidelines.
11. Key safety warning: ⚠️ Complications of bacterial sinusitis (orbital cellulitis, cavernous sinus thrombosis, brain abscess, meningitis) are medical/surgical emergencies. If the patient develops periorbital oedema, proptosis, visual changes, severe headache, high fever, or neurological signs — immediate hospitalisation and IV antibiotics (NOT oral cefprozil).
12. Dose adjustment: Renal impairment — adjust if CrCl <30 mL/min.

---

Indication 4: ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB) / AECOPD — Moderate Severity

1. When to prefer cefprozil for AECOPD:
2. • ✅ When oral second-generation cephalosporin is indicated for moderate AECOPD (Anthonisen Type I or II) in outpatient setting
   • ✅ When amoxicillin-clavulanate is not tolerated (GI intolerance — cefprozil has lower diarrhoea rates)
   • ✅ When patient is unable to take amoxicillin-clavulanate with food reliably (cefprozil is food-independent)
   • ✅ Covers the three commonest AECOPD pathogens: H. influenzae, S. pneumoniae, M. catarrhalis
3. When NOT to use:
4. • ⛔ NOT for mild AECOPD without purulent sputum (antibiotics unlikely to benefit — manage with bronchodilators, systemic corticosteroids)
   • ⛔ NOT for severe AECOPD requiring hospitalisation/ICU (requires IV antibiotics — cefprozil has no IV form)
   • ⛔ NOT if Pseudomonas risk factors present (frequent exacerbations, structural lung disease, chronic systemic steroids, recent hospitalisation, FEV1 <30% predicted) — use anti-pseudomonal agent
   • ⛔ NOT for suspected lower respiratory tract infection with aspiration component (no anaerobic coverage)
5. NLEM India: ❌ Not listed. Amoxicillin-clavulanate is NLEM-listed for this indication.
6. Time to expected clinical response: Improvement in sputum purulence and dyspnoea within 48–72 hours. CRP (if checked) should decline by >50% by day 3–4.
7. Treatment failure criteria: Persistent purulent sputum, worsening dyspnoea, new fever, rising CRP at 72 hours → consider broadening coverage (respiratory fluoroquinolone), hospitalisation if deteriorating, sputum culture. ⚠️ India-specific: Always consider tuberculosis in non-resolving lower respiratory symptoms — obtain sputum AFB smear and GeneXpert.
8. Baseline investigations:RECOMMENDED: Chest X-ray (to exclude pneumonia, TB), SpO₂. OPTIONAL: Sputum Gram stain/culture, CBC, CRP. MANDATORY for recurrent AECOPD: Spirometry (when stable, to confirm COPD diagnosis and severity).
9. Specialist initiation: Not required for outpatient AECOPD — primary care appropriate. Refer to Pulmonology if ≥2 moderate exacerbations per year, hospitalisation for exacerbation, or diagnostic uncertainty.
10. Indian guideline source: API Textbook — COPD chapter; GOLD 2024 Report; ICMR AMR Guidelines 2019.
11. Key safety warning: ℹ️ Cefprozil treats the bacterial component of AECOPD only — concurrent bronchodilator intensification (SABA ± SAMA) and systemic corticosteroids (prednisolone 30–40 mg × 5 days) remain the cornerstone of AECOPD management.
12. Dose adjustment: Renal impairment — adjust if CrCl <30 mL/min.

---

Indication 5: COMMUNITY-ACQUIRED PNEUMONIA (CAP) — Mild, Outpatient

1. When to prefer cefprozil for CAP:
2. • ✅ When non-severe outpatient CAP (CURB-65 = 0–1, CRB-65 = 0) requires an oral beta-lactam with H. influenzae coverage beyond first-generation cephalosporins
   • ✅ When amoxicillin-clavulanate is not tolerated (GI intolerance) or patient cannot take food reliably (cefprozil is food-independent)
   • ✅ Second-line after amoxicillin/amoxicillin-clavulanate failure in outpatient CAP
   • ✅ Non-severe penicillin allergy
3. When NOT to use:
4. • ⛔ NOT for moderate-severe CAP (CURB-65 ≥2, hospitalised) — requires IV antibiotics (cefprozil has no IV form)
   • ⛔ NOT for severe CAP requiring ICU admission — use IV ceftriaxone or piperacillin-tazobactam + macrolide
   • ⛔ NOT as monotherapy if atypical pneumonia suspected — must combine with macrolide or doxycycline
   • ⛔ NOT for aspiration pneumonia (no anaerobic coverage)
   • ⛔ NOT for hospital-acquired pneumonia (HAP/VAP) — MDR organisms require broader agents
   • ⛔ NOT for penicillin-resistant pneumococcal pneumonia (MIC >2 mg/L for penicillin)
   • ⛔ NOT for suspected TB — ⚠️ In India, TB must be considered in any non-resolving pneumonia
5. NLEM India: ❌ Not listed. Amoxicillin is NLEM-listed for outpatient CAP. Ceftriaxone injection is NLEM-listed for hospitalised CAP.
6. Time to expected clinical response: Defervescence and symptom improvement within 48–72 hours. CRP should decline by ≥50% at day 3–4.
7. Treatment failure at 72 hours: Reassess: complications (empyema, lung abscess), drug-resistant organism, atypical pathogen, alternative diagnosis (TB, malignancy, eosinophilic pneumonia). Obtain sputum culture, chest X-ray if not done. Hospitalise if deteriorating.
8. Baseline investigations:MANDATORY: Chest X-ray, SpO₂, allergy history. RECOMMENDED: CBC, CRP. OPTIONAL: Sputum Gram stain/culture, blood cultures (if febrile), renal function.
9. Specialist initiation: Not required for non-severe outpatient CAP — primary care appropriate. Hospitalise if CURB-65 ≥2 or significant comorbidity.
10. Indian guideline source: API Textbook — CAP chapter; ICMR AMR Treatment Guidelines 2019; Joint ICS-NCDC CAP Guidelines. ℹ️ API Textbook lists oral beta-lactams (amoxicillin-clavulanate, oral cephalosporins) as outpatient CAP options, combined with macrolide for atypical coverage.
11. Key safety warning: ⚠️ Oral cefprozil is appropriate ONLY for non-severe, outpatient-managed CAP (CURB-65 0–1). If SpO₂ <92%, respiratory rate >30/min, confusion, or hypotension → hospitalise for IV therapy. Cefprozil has no IV formulation — if the patient deteriorates, immediate transition to a parenteral antibiotic is needed.
12. Dose adjustment: Renal impairment — adjust if CrCl <30 mL/min.

---

Indication 6: SKIN AND SOFT TISSUE INFECTIONS (SSTI) — Mild to Moderate, Community-Acquired

1. When to prefer cefprozil for SSTI:
2. • ✅ Mild-moderate community-acquired SSTI (cellulitis, erysipelas, wound infections, impetigo) where both staphylococcal (MSSA) AND streptococcal coverage is needed
   • ✅ When oral therapy is sufficient (non-severe, no systemic toxicity)
   • ✅ GI intolerance to amoxicillin-clavulanate
   • ✅ Non-severe penicillin allergy
3. When NOT to use:
4. • ⛔ MRSA SSTI — cefprozil is inactive. CA-MRSA prevalence in Indian SSTIs varies from 10–40% depending on region and setting. Use cotrimoxazole, doxycycline, clindamycin, or linezolid for suspected/confirmed MRSA.
   • ⛔ Serious/deep MSSA infections (bacteraemia, endocarditis, osteomyelitis) — cefprozil is oral-only and has NO IV form; use IV cefazolin or IV cloxacillin
   • ⛔ Polymicrobial SSTIs (bite wounds, diabetic foot infections, perianal abscess) — need anaerobic coverage. Use amoxicillin-clavulanate, ampicillin-sulbactam, or add metronidazole.
   • ⛔ Necrotising fasciitis — surgical emergency + IV broad-spectrum antibiotics
   • ⛔ Abscess requiring drainage — antibiotics alone are insufficient; abscess drainage is the primary treatment
5. NLEM India: ❌ Not listed. Cephalexin (NLEM) and amoxicillin-clavulanate (NLEM) are listed alternatives for SSTI.
6. Time to expected clinical response: Reduction in erythema, swelling, and tenderness within 48–72 hours. Mark the border of erythema at baseline to objectively assess progression vs improvement.
7. Treatment failure criteria: Expanding erythema at 72 hours despite compliance, development of systemic signs (fever, leucocytosis), fluctuance suggesting abscess, or clinical suspicion of necrotising infection. Consider: wound culture, imaging (USS for abscess), MRSA coverage, surgical referral.
8. Baseline investigations:OPTIONAL: Wound culture and sensitivity (especially if recurrent, post-surgical, or prior antibiotic failure). Most uncomplicated community-acquired SSTIs do not require baseline labs.
9. Specialist initiation: Not required — primary care appropriate.
10. Indian guideline source: API Textbook — SSTI chapter; ICMR AMR Guidelines 2019; IADVL Guidelines (for dermatological infections).
11. Key safety warning: ⚠️ Always assess for underlying conditions predisposing to complicated SSTI: diabetes mellitus (extremely common in Indian population — consider diabetic foot infection), immunosuppression, peripheral vascular disease, chronic kidney disease. These patients may require broader coverage and lower threshold for parenteral therapy.
12. Dose adjustment: Renal impairment — adjust if CrCl <30 mL/min.

---

Indication 7: URINARY TRACT INFECTIONS (UTI) — Uncomplicated, Culture-Directed

1. When to prefer cefprozil for UTI:
2. • ✅ ONLY after culture and sensitivity confirms a susceptible, non-ESBL organism (E. coli, Proteus, Klebsiella — non-ESBL)
   • ✅ When first-line agents (nitrofurantoin, fosfomycin) are not tolerable or appropriate
   • ✅ Convenient BID dosing with food-independent absorption
3. When NOT to use:
4. • ⛔ NOT empirically for UTI in India — ESBL prevalence is too high
   • ⛔ NOT for complicated UTI / pyelonephritis requiring IV therapy (cefprozil is oral-only)
   • ⛔ NOT for catheter-associated UTI without susceptibility data
   • ⛔ NOT for Enterococcal UTI (cephalosporins have no enterococcal activity — use amoxicillin or ampicillin)
5. NLEM India: ❌ Not listed. Nitrofurantoin is NLEM-listed as first-line for uncomplicated UTI.
6. Time to expected clinical response: Symptom improvement within 48–72 hours.
7. Baseline investigations:MANDATORY: Urine culture and sensitivity before starting. Urine routine microscopy.
8. Specialist initiation: Not required — primary care appropriate once susceptibility confirmed.
9. Indian guideline source: ICMR AMR Treatment Guidelines 2019 (recommend culture-directed therapy when cephalosporins are considered for UTI in India).
10. Key safety warning: ⚠️ Do NOT assume susceptibility based on organism identity alone — always check the individual isolate’s antibiogram. Even community-acquired E. coli may be ESBL-producing in 20–40% of cases in urban India.
11. Dose adjustment: Renal impairment — adjust if CrCl <30 mL/min.

---

Secondary Indications — Adults Only (Off-label, if any)

---

Off-Label Indication 1: ORAL STEP-DOWN THERAPY — Following IV Cephalosporin for Various Infections

• ℹ️ This is NOT a same-molecule step-down (cefprozil has no IV form). It is a cross-molecule step-down from IV cefuroxime sodium to oral cefprozil — both second-generation cephalosporins with overlapping spectra.
• 💡 The pharmacokinetic advantage: Cefprozil achieves higher and more predictable serum levels (~95% bioavailability, food-independent) than cefuroxime axetil (~37–52%, food-dependent) for oral step-down — particularly relevant for patients with unreliable food intake during early convalescence.
• Evidence quality: Moderate (pharmacokinetic rationale + clinical practice; no head-to-head RCT of cefprozil vs cefuroxime axetil for oral step-down)
• Indian source: Indian hospital practice; pharmacokinetic principles per Goodman & Gilman
• Clearly marked: OFF-LABEL but accepted standard practice in India

---

Off-Label Indication 2: SECONDARY PROPHYLAXIS — Recurrent GAS Pharyngitis

• Evidence quality: Moderate (RCTs comparing cephalosporins vs penicillin for GAS pharyngitis show slightly higher eradication rates with cephalosporins — Casey JR, Pichichero ME. Pediatr Infect Dis J 2004; meta-analysis)
• Indian context: Recurrent GAS pharyngitis is common in Indian children in crowded settings. Some ENT specialists use cephalosporins for treatment of individual recurrences when amoxicillin has failed. Standard rheumatic fever prophylaxis (benzathine penicillin G) is a DIFFERENT indication and is NOT replaced by cefprozil.
• Clearly marked: OFF-LABEL
• Specialist only — ENT or paediatric infectious disease

---

Off-Label Indication 3: ACUTE BRONCHITIS — Bacterial Superinfection

• Bacterial superinfection is strongly suspected (persistent purulent sputum >10–14 days with worsening symptoms)
• Patient has significant comorbidity (COPD, bronchiectasis, immunosuppression)
• The line between “acute bronchitis with bacterial superinfection” and “mild CAP” is often blurred

• Evidence quality: Weak (most RCTs of antibiotics for acute bronchitis show minimal benefit in otherwise healthy adults)
• Indian context: ⚠️ In Indian practice, antibiotics for acute bronchitis are massively overprescribed. Cefprozil (or any antibiotic) should NOT be prescribed for uncomplicated viral bronchitis. Prescribers should counsel patients that green/yellow sputum does not automatically indicate bacterial infection.
• Clearly marked: OFF-LABEL

---

Off-Label Indication 4: DENTAL INFECTIONS — Periapical Abscess, Post-Extraction Prophylaxis

• Evidence quality: Weak (extrapolated from general beta-lactam dental infection data; no RCTs specifically with cefprozil for dental infections)
• ℹ️ Infective Endocarditis (IE) prophylaxis — dental procedures: Standard IE prophylaxis for penicillin-allergic patients undergoing dental procedures is clindamycin 600 mg oral or azithromycin 500 mg oral (single dose, 30–60 min before procedure). Cefprozil is NOT the standard recommendation for IE prophylaxis in guidelines (cephalexin 2 g oral single dose is the standard cephalosporin option for non-severe penicillin allergy per AHA/ESC guidelines adapted for India). However, if cephalexin is unavailable: cefprozil 1 g oral as a single dose 30–60 minutes before the procedure may be considered as a reasonable pharmacokinetic substitute (same generation, similar spectrum) — but this is off-label and without specific guideline support.
• Clearly marked: OFF-LABEL

---

Summary Table — All Adult Indications

---

PAEDIATRIC DOSING (Specialist Only)

---

General Notes — Paediatric

• Monitor for hypersensitivity reactions (rash, urticaria, anaphylaxis) — especially with first dose and in children with personal/family history of atopy or penicillin allergy
• Monitor for antibiotic-associated diarrhoea — common (~2–6%) and usually mild; if severe/bloody/persistent → rule out Clostridioides difficile infection (rare in children but increasing in India)
• Monitor for oral/nappy-area candidiasis — common with prolonged courses; treat symptomatically with topical antifungals
• No routine laboratory monitoring required for standard 5–14 day courses in otherwise healthy children with normal renal function

• ≥6 months: Safety and efficacy of cefprozil are established from 6 months of age onwards for most labelled indications (AOM, pharyngitis, sinusitis, SSTI)
• 2–12 years: Standard paediatric weight-based dosing
• <6 months: ⚠️ Limited data. Safety and efficacy NOT well-established below 6 months. Use only under paediatric specialist supervision in exceptional circumstances. For infants <6 months with bacterial infections, IV antibiotics (ampicillin + gentamicin for neonatal sepsis; IV cefuroxime or ceftriaxone for older infant infections) are preferred.
• Neonates (<28 days): ⛔ No neonatal dosing established. Do NOT use cefprozil in neonates. For neonatal infections, use IV antibiotics under NICU supervision (standard empirical neonatal sepsis regimen: ampicillin + gentamicin per NNF/IAP guidelines).

• ✅ Oral suspension (125 mg/5 mL, 250 mg/5 mL): Available and well-suited for paediatric use. This is the primary paediatric formulation.
• ✅ Tablets (250 mg, 500 mg): Suitable for older children (typically ≥6 years) who can swallow tablets whole.

• Infants 6–12 months: Renal function is maturing; half-life may be slightly prolonged compared to older children. Standard weight-based dosing (mg/kg BID) is adequate.
• Children 1–12 years: Weight-adjusted clearance and Vd are similar to adults. Standard weight-based dosing applies.
• Adolescents ≥12 years or ≥40 kg: Use adult dosing (250–500 mg q12h per indication).

---

PAEDIATRIC DOSING REFERENCE TABLE

---

Neonatal Dosing

• ⛔ Cefprozil is an oral-only drug with NO parenteral formulation. Neonates (<28 days) with suspected bacterial infections require IV antibiotics under NICU supervision.
• Standard empirical neonatal sepsis regimen per NNF India / IAP / WHO: IV ampicillin + IV gentamicin.
• Cefprozil is NOT appropriate for neonatal infections due to: (a) lack of IV form, (b) lack of PK data in neonates, © neonatal infections are typically serious and require parenteral therapy, (d) neonatal gut absorption of oral drugs is variable and unreliable.
• Do NOT use cefprozil in neonates.

---

Primary Indications — Paediatric (Approved / Standard in India)

---

Paediatric Indication 1: ACUTE OTITIS MEDIA (AOM) — Second-Line

Patient: 3-year-old child weighing 14 kg with AOM (second episode in 3 months, failed amoxicillin)

Dose calculation: 15 mg/kg/dose = 15 × 14 = 210 mg per dose

Using 125 mg/5 mL suspension: 210 mg ÷ 125 mg/5 mL = 8.4 mL per dose
→ Practically round to 8.5 mL (or 8 mL for convenience)

Using 250 mg/5 mL suspension: 210 mg ÷ 250 mg/5 mL = 4.2 mL per dose
→ Practically round to 4 mL

Frequency: Twice daily (q12h) — e.g., 8 AM and 8 PM
Duration: 10 days (child is <6 years)
With or without food: Either — no food requirement

1. When to prefer cefprozil: Second-line after high-dose amoxicillin failure (no improvement at 48–72 hours) or amoxicillin intolerance. Primary competitor: cefuroxime axetil and amoxicillin-clavulanate. Cefprozil is preferred over cefuroxime axetil when taste compliance is a concern (very common in 6 months – 4 years age group). API Textbook and IAP Guidelines list cephalosporins as second-line for AOM.
2. When NOT to use:
3. • ⛔ NOT first-line — first-line is high-dose amoxicillin (80–90 mg/kg/day divided q8–12h)
   • ⛔ NOT for complicated AOM (mastoiditis, facial nerve palsy, intracranial complications) — IV antibiotics + ENT referral
   • ⛔ NOT for children <6 months with AOM — higher risk of serious bacterial infection; paediatric specialist assessment needed; may require IV therapy
   • ⛔ NOT for CSOM (chronic suppurative otitis media) — different pathophysiology and microbiology
4. NLEM India: ❌ Not listed. Amoxicillin is NLEM-listed first-line for AOM.
5. Time to expected clinical response: Improvement in ear pain, reduced irritability, defervescence within 48–72 hours. Complete resolution of middle ear effusion may take 4–12 weeks (this is normal — persistent effusion does NOT indicate treatment failure).
6. Treatment failure criteria: Persistent fever, ear pain, or irritability at 72 hours → consider: tympanocentesis for culture-directed therapy, switch to amoxicillin-clavulanate (if not already used), or IM ceftriaxone 50 mg/kg × 3 days. ENT referral if recurrent.
7. Mandatory baseline investigations: Otoscopic examination. No laboratory investigations required for uncomplicated AOM.
8. Specialist initiation: Not required — primary care/paediatrician appropriate.
9. Indian guideline source: IAP Guidelines on AOM Management; API Textbook — ENT Infections; WHO IMNCI Guidelines.
10. Key safety warning: ⚠️ Observation option for mild AOM in children ≥2 years: IAP and AAP guidelines allow an initial “watchful waiting” period of 48–72 hours WITHOUT antibiotics for non-severe AOM in children ≥2 years with unilateral disease and no comorbidities. If symptoms worsen or do not improve → start antibiotics. This reduces unnecessary antibiotic prescribing.
11. Dose adjustment: Renal impairment — rare in paediatric AOM patients; adjust if known CKD. Use Schwartz formula for paediatric eGFR.

---

Paediatric Indication 2: GAS PHARYNGOTONSILLITIS — Second-Line

Patient: 6-year-old child weighing 20 kg with confirmed GAS pharyngitis (RADT positive). Previous amoxicillin course → GAS recurrence within 4 weeks.

Dose (OD regimen): 15 mg/kg = 15 × 20 = 300 mg once daily

Using 125 mg/5 mL suspension: 300 mg ÷ 125 mg/5 mL = 12 mL once daily
Using 250 mg/5 mL suspension: 300 mg ÷ 250 mg/5 mL = 6 mL once daily

Duration: 10 days — no exceptions in India (rheumatic fever prevention)
With or without food: Either

1. When to prefer cefprozil:
2. • ✅ Second-line after amoxicillin/penicillin failure or recurrence
   • ✅ Non-severe penicillin allergy
   • ✅ Once-daily dosing — significantly better adherence than penicillin V (TDS-QID × 10 days) or even amoxicillin (BID-TDS × 10 days). In Indian families with working caregivers, school-going children, and difficulty maintaining mid-day doses, OD dosing is a practical advantage.
   • ✅ Pleasant taste (suspension) — important for younger children
3. ⚠️ 10-day course is NON-NEGOTIABLE:
   India’s rheumatic heart disease burden is among the highest globally. Incomplete GAS eradication → risk of acute rheumatic fever (ARF) → chronic RHD. ⛔ Do NOT prescribe shorter courses (3-day, 5-day cephalosporin courses described in some international guidelines are NOT appropriate for the Indian RHD risk context). 10-day full-course therapy is mandatory per IAP Guidelines and API Textbook.
4. NLEM India: ❌ Not listed. Penicillin V and amoxicillin are NLEM-listed first-line agents for GAS pharyngitis.
5. Indian guideline source: IAP Guidelines on GAS Pharyngitis (penicillin/amoxicillin first-line; cephalosporins as second-line); API Textbook.

---

Paediatric Indication 3: ACUTE BACTERIAL SINUSITIS — Second-Line

• Second-line after amoxicillin or amoxicillin-clavulanate failure/intolerance
• Diagnosis requires clinical criteria (symptoms ≥10 days without improvement, or “double sickening,” or severe onset) — do NOT treat viral upper respiratory infections with antibiotics
• NLEM India: ❌ Not listed
• IAP Guidelines; API Textbook — ENT Infections chapter

---

Paediatric Indication 4: COMMUNITY-ACQUIRED PNEUMONIA — Mild, Outpatient (≥5 years)

• ℹ️ For paediatric CAP in children <5 years, first-line per IAP/WHO is oral amoxicillin (high-dose). Cefprozil is typically used only in children ≥5 years where beta-lactamase-producing H. influenzae is a concern (with Hib vaccine coverage, this is increasingly rare).
• ⚠️ For non-severe paediatric CAP, IAP first-line is oral amoxicillin (90 mg/kg/day divided BID-TDS). Cefprozil is second-line.
• ⚠️ India-specific: Always consider tuberculosis in non-resolving paediatric pneumonia — sputum/gastric aspirate for AFB/GeneXpert if available.
• NLEM India: ❌ Not listed. Amoxicillin is NLEM first-line for paediatric CAP.
• Indian guideline source: IAP Guidelines on Paediatric CAP (revised 2021); WHO Pneumonia Guidelines.

---

Paediatric Indication 5: SKIN AND SOFT TISSUE INFECTIONS — Mild to Moderate

• ⛔ NOT for MRSA SSTI — use cotrimoxazole or clindamycin
• ⛔ NOT for bite wounds (need anaerobic coverage — amoxicillin-clavulanate preferred)
• ⛔ NOT for severe/complicated SSTI — requires IV therapy
• NLEM India: ❌ Not listed. Cephalexin and amoxicillin-clavulanate are NLEM-listed for SSTI.

---

Secondary Indications — Paediatric (Off-label, if any)

---

Off-Label Paediatric Indication 1: ACUTE BRONCHITIS — Bacterial Superinfection in Children with Chronic Lung Disease

• Evidence quality: Weak (extrapolated from adult AECOPD data; no paediatric RCTs for cefprozil in this indication)
• Clearly marked: OFF-LABEL
• Specialist only — Paediatric Pulmonology

---

Off-Label Paediatric Indication 2: PERIORBITAL (PRESEPTAL) CELLULITIS — Mild, Outpatient

• Evidence quality: Weak (case series, expert practice; amoxicillin-clavulanate is more commonly used)
• Clearly marked: OFF-LABEL
• Specialist only — Paediatrician/Ophthalmologist

---

Paediatric Secondary Indications Summary Table

---

MISSED DOSE / DELAYED DOSE GUIDANCE

---

Dosing Frequency Context

---

For q12h (Twice-Daily) Dosing — Outpatient

For q24h (Once-Daily) Dosing — GAS Pharyngitis

---

PRN Dosing

---

Prolonged Non-Adherence / Drug Holiday Guidance

• Cefprozil is used as a finite-duration antibiotic course (typically 5–14 days). Not chronic therapy.
• No rebound effects or withdrawal syndrome upon stopping.
• No immunogenicity concern (not a biologic).

• Sub-therapeutic levels will have been present for ≥24 hours → bacterial regrowth risk
• Resume immediately at the full dose — no re-titration needed (wide therapeutic index)
• Extend the total course duration by the number of missed days to ensure adequate total treatment exposure
• If treating a serious infection (e.g., AOM with complications, moderate SSTI) and multiple doses have been missed → reassess clinically. Consider:
• • Restarting the full course
  • Switching to a different antibiotic if the original course was significantly interrupted
  • Obtaining cultures if symptoms have worsened

---

Counselling Point for Patients/Caregivers (Missed Dose)

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

---

A. ORAL TABLETS — Cefprozil

---

B. ORAL SUSPENSION — Cefprozil (Powder for Reconstitution)

• “Keep the bottle in the fridge after mixing with water. If you do not have a fridge, store it in the coolest part of the house — away from the kitchen, stove, and windows. Keep the bottle tightly closed.”
• “Use the medicine within 10 days if you cannot keep it in a fridge.”
• “If the medicine changes colour (becomes dark) or smells different, do NOT use it — get a new bottle.”

---

C. SPECIAL ADMINISTRATION NOTES

---

D. STORAGE SUMMARY

E. COLD-CHAIN GUIDANCE

• Cefprozil dry powder (tablets and unreconstituted dry syrup) does NOT require cold-chain storage. Stable at room temperature (below 25°C, acceptable up to 30°C for short periods).
• After reconstitution of oral suspension: refrigeration is recommended but not absolutely required (stable at ≤25°C for 14 days).
• No special transport cold-chain requirements for dry formulations.
• ℹ️ Indian context: Cefprozil’s room-temperature stability for dry formulations makes it suitable for supply to PHCs, CHCs, and remote areas. After reconstitution, refrigeration is ideal but not mandatory — acceptable at room temperature for 14 days if ambient temperature is ≤25°C.

---

RENAL ADJUSTMENT

---

eGFR Formula Specification

Rationale

• Half-life in normal renal function: ~1.3 hours
• Half-life in CrCl <30 mL/min: ~5.2–5.9 hours (approximately 4-fold increase)
• Half-life on haemodialysis: ~2.5 hours during HD, ~5.9 hours between sessions
• Adjustment is by dose reduction or interval extension depending on CrCl

---

Adult Renal Dosing Adjustment Table

---

Paediatric Renal Adjustment

---

Augmented Renal Clearance (ARC)

• An oral-only drug
• NOT used in ICU settings
• NOT used for serious/life-threatening infections requiring maximal drug levels

---

Key Practical Notes for Renal Adjustment in Indian Practice

---

HEPATIC ADJUSTMENT

---

✅ NO HEPATIC DOSE ADJUSTMENT IS REQUIRED

---

Hepatotoxicity Risk of Cefprozil

---

Concurrent Hepatotoxin Note

---

CONTRAINDICATIONS

---

1. ⛔ Known Severe Hypersensitivity (Anaphylaxis) to Cefprozil or Any Cephalosporin

• Rationale: Risk of recurrent IgE-mediated anaphylaxis — potentially fatal. Includes documented angioedema, severe urticaria with haemodynamic compromise, laryngospasm, bronchospasm, or cardiovascular collapse to ANY cephalosporin.
• ℹ️ Mild, delayed, non-IgE-mediated reactions to other cephalosporins (maculopapular rash without systemic features, occurring >72 hours after exposure) are NOT absolute contraindications to cefprozil but require cautious use with monitoring (see Cautions).

---

2. ⛔ Known Anaphylaxis to Cefprozil Specifically

• ⛔ Avoid cefprozil permanently. Other cephalosporins with different R1/R2 side chains may be usable after formal allergy evaluation by an allergist/immunologist.
• Alternatives: azithromycin (respiratory infections), cotrimoxazole (UTI, SSTI), fluoroquinolone (adults only — levofloxacin for CAP), clindamycin (SSTI, GAS pharyngitis).

---

Allergy Cross-Reactivity

---

Penicillin Allergy Decision Table for Cefprozil

---

CAUTIONS

---

⚠️ High-Priority Cautions

---

• Cefprozil is ~60–70% renally eliminated. Half-life increases from ~1.3 hours to ~5.2–5.9 hours when CrCl <30 mL/min.
• Monitoring: Calculate CrCl (Cockcroft-Gault) before prescribing — especially in elderly Indian patients where serum creatinine may underestimate true renal impairment.
• Action: Reduce dose to 50% of standard dose; maintain q12h frequency (see Renal Adjustment, Part 3).
• ⚠️ Failure to adjust → drug accumulation → increased risk of dose-dependent adverse effects (GI disturbance, CNS effects at very high levels).

---

• Cross-reactivity ~2–5%. Use the Penicillin Allergy Decision Table above to classify risk.
• For non-severe penicillin allergy: monitored first dose in a clinical setting with adrenaline available.
• For severe/anaphylactic penicillin allergy: formal allergy evaluation or non-beta-lactam alternative.

---

• ⚠️ In Indian hospital and even community settings, ESBL prevalence among E. coli and Klebsiella is 40–70% (hospital) and 20–40% (community). Cefprozil is COMPLETELY INEFFECTIVE against ESBL producers.
• Action: Always obtain cultures (especially urine C&S) before using cefprozil for gram-negative infections. If ESBL confirmed: switch immediately. Do NOT use cefprozil empirically for UTI in high-ESBL-prevalence Indian settings.

---

• All cephalosporins carry CDI risk. Second-generation cephalosporins carry lower CDI risk than third-generation cephalosporins (ceftriaxone — among the highest-risk antibiotics for CDI). This is a stewardship advantage.
• ⚠️ CDI risk is highest in: elderly (≥60 years), hospitalised patients, patients on concurrent PPI therapy, patients with recent antibiotic exposure (within 3 months), immunosuppressed patients.
• Monitoring: Report new-onset watery diarrhoea (≥3 loose stools/day), especially if bloody, with fever, or with abdominal cramps. Test for C. difficile toxin if suspected. Use the shortest effective course.

---

• ⚠️ Some cefprozil oral suspension formulations contain aspartame (an artificial sweetener that is a source of phenylalanine). Aspartame is metabolised to phenylalanine, which accumulates in patients with phenylketonuria (PKU).
• Action: Check the specific brand’s product insert for aspartame content before prescribing oral suspension to patients with known PKU. If aspartame is present: use tablets (if the child can swallow them) or an alternative antibiotic without aspartame.
• ℹ️ PKU is rare in India but is included in newborn screening programmes in some centres. This caution applies to the suspension formulation only — tablets do NOT contain aspartame.

---

Standard Cautions

---

• Prolonged use (>10–14 days) may lead to overgrowth of non-susceptible organisms: oral candidiasis, vaginal candidiasis, antibiotic-associated diarrhoea. Risk is lower than with third-generation cephalosporins (narrower spectrum = less flora disruption).
• Treat candidiasis symptomatically with topical antifungals (clotrimazole, nystatin).

---

• Very high-dose cephalosporins in renal impairment can rarely lower seizure threshold — this is primarily a concern with high-dose IV cephalosporins (cefepime, imipenem) rather than oral cefprozil at standard doses. Risk with cefprozil at standard oral doses is extremely low.
• If CrCl <30 mL/min AND seizure history: use renal-adjusted dosing.

---

---

• ⛔ NOT recommended. No neonatal dosing established. No IV formulation. Neonates with infections require IV antibiotics under NICU supervision.

---

• ⚠️ Safety and efficacy data limited below 6 months. Use only under paediatric specialist supervision in exceptional circumstances.

---

• ⛔ Do NOT use cefprozil for gonorrhoea — gonococcal resistance to oral cephalosporins is widespread. Use ceftriaxone 500 mg IM per NACO/ICMR guidelines. Listed as a caution (not contraindication) because it is a treatment failure risk rather than a direct safety risk — but the clinical consequence (untreated gonorrhoea with complications) is serious.

---

• Cephalosporins (class effect — primarily via gut flora disruption reducing bacterial vitamin K synthesis) may modestly increase INR in patients on warfarin/acenocoumarol.
• Monitor INR within 3–5 days of starting and after stopping cefprozil in anticoagulated patients.
• Adjust anticoagulant dose as needed.

---

• Some cefprozil oral suspension formulations contain sucrose. The amount per dose is small and unlikely to significantly affect blood glucose at standard doses.
• ℹ️ For diabetic patients concerned about sugar intake: tablets (no sucrose) are preferred. If suspension is necessary: the sucrose content per 5 mL dose is typically 2–3 g — negligible glycaemic impact.

---

PREGNANCY

---

Overall Safety Statement

---

Trimester-Specific Risk Assessment

---

Teratogenicity Window

---

Preferred Alternatives in Indian Obstetric Practice

---

Monitoring During Pregnancy

• Mother: Standard adverse effect monitoring. No specific additional monitoring for cefprozil.
• Fetus/Neonate: No specific fetal monitoring required. No known fetal toxicity.

---

Pre-Conception Counselling

---

Pregnancy Prevention Programme / Registry

---

Fertility Effects

---

LACTATION

---

Overall Compatibility

---

What to Monitor in the Breastfed Infant

• Loose stools or mild diarrhoea — most common possible effect; transient, due to alteration of infant gut flora
• Nappy rash — secondary to diarrhoea
• Oral candidiasis (thrush) — uncommon
• Allergic skin rash — very rare; possible sensitisation
• ℹ️ In most cases, no adverse effects are observed in the breastfed infant.

---

Preferred Alternatives (If Cefprozil Not Recommended)

---

Timing Advice

---

Effect on Milk Production

---

Temporary Incompatibility Guidance

---

ELDERLY

---

Definition

---

Dosing in Elderly

---

PK Considerations in Elderly

• Low muscle mass (sarcopaenia — common in elderly Indian population)
• Vegetarian diet (lower dietary creatinine generation)
• Small body habitus (low body weight — average elderly Indian woman: 45–55 kg)

---

Extra Risks Specific to Elderly

---

Common Clinical Scenarios in Elderly Indian Patients

---

Anticholinergic Burden

---

Beers Criteria / STOPP-START Relevance

---

Deprescribing Guidance

---

MAJOR DRUG INTERACTIONS

---

• Zero CYP450 substrate/inhibitor/inducer activity
• Zero hepatic metabolism
• No significant drug transporter interactions (P-gp, OATP, OAT, OCT, MATE, BCRP) at therapeutic oral concentrations
• Low protein binding (~36%) — no clinically significant displacement interactions

---

---

Major Food-Drug Interactions

---

Major Herb-Drug / Traditional Medicine Interactions

---

MODERATE DRUG INTERACTIONS

---

---

Moderate Food-Drug Interactions

---

Traditional Medicine Interactions (Moderate)

---

COMMON ADVERSE EFFECTS

---

---

Very Common (≥10%)

---

Common (1–10%)

---

Dose-Response Threshold for Common ADRs

• Diarrhoea and GI effects: Modestly dose-dependent — more common at 500 mg BID than 250 mg BID and with courses >7 days.
• Rash: Not clearly dose-dependent — more related to individual immunological predisposition.
• Eosinophilia: Not dose-dependent.

---

Comparison of GI Adverse Effect Rates: Cefprozil vs Key Comparators

---

SERIOUS ADVERSE EFFECTS

---

---

---

Antidote / Reversal Information

---

CDSCO Safety Alerts / Black Box Warnings

---

Early Warning Signs — Patient/Caregiver/Nursing Staff Education

• Skin rash with blisters, peeling skin, or sores inside the mouth/eyes/private parts
• Swelling of face, lips, tongue, or throat; difficulty breathing or swallowing
• Severe watery or bloody diarrhoea with stomach cramps and fever — even if it happens weeks after finishing the medicine
• Yellow colour of the eyes or skin (jaundice) — very rare
• Unusual bruising or bleeding from gums/nose
• Reduced urine output or blood in urine
• High fever with rash and joint pain"

---

MONITORING REQUIREMENTS

---

Baseline (Before Starting)

---

After Initiation / Dose Change

---

Long-Term / Maintenance Monitoring

---

Therapeutic Drug Monitoring (TDM)

---

When to Stop Monitoring

• For standard 5–14 day courses: no monitoring beyond clinical response assessment at 48–72 hours and end-of-course clinical review.
• For anticoagulated patients: continue INR monitoring until 5–7 days after stopping cefprozil, then return to routine INR schedule.

---

Resource-Limited Setting Surrogates — Summary Table

---

PATIENT COUNSELLING

---

What This Medicine Is For

---

How to Take It

• “Take this tablet twice a day — once in the morning and once in the evening, about 12 hours apart (for example: 8 AM and 8 PM).”
• “You can take it with or without food — it works equally well either way. Take it at whatever time is easiest for you to remember.”
• “Swallow the tablet whole with a full glass of water.”
• “If your doctor has prescribed it once a day (for throat infection): take it at the same time every day.”
• “Complete the full course as prescribed by your doctor, even if you feel better before the course is finished.”

• “Shake the bottle well before every dose.”
• “Use the measuring cup or oral syringe that comes with the bottle — do NOT use a household spoon (it gives the wrong amount and can cause under- or over-dosing).”
• “You can give the medicine with or without food.”
• ℹ️ “This liquid has a pleasant fruity taste — most children accept it well. If your child dislikes it, you can mix the measured dose with a small spoonful of curd (dahi), mashed banana, or honey (only for children over 1 year) immediately before giving. Make sure the child takes ALL of the mixture.”
• “After the chemist adds water to the powder, store the bottle in the fridge if possible. If you do not have a fridge, keep it in the coolest part of your house. Use within 14 days. Throw away any leftover liquid after 14 days.”

---

What to Do If You Miss a Dose

• “If you remember within 6 hours of the missed time, take the dose right away. Then continue at your regular time.”
• “If more than 6 hours have passed (i.e., your next dose is due in less than 6 hours), skip the missed dose. Take the next dose at its regular time.”
• “Never take two doses at the same time to make up for a missed dose.”
• “If your child vomits within 30 minutes of taking the medicine, give the same dose again.”

---

Common Side Effects to Expect

• “You may get loose stools or mild diarrhoea — this is common and usually goes away on its own. Drink plenty of fluids (water, ORS, coconut water, buttermilk/chaas). If the diarrhoea becomes very severe, watery, bloody, or lasts more than 2 days, see your doctor.”
• “You may feel mild nausea or stomach discomfort — this usually gets better within a day or two.”
• “Children may develop a red rash in the nappy area — this is usually due to loose stools. Keep the area clean and dry, and apply barrier cream.”

---

Warning Signs — Come to Hospital Immediately If You Develop Any of These

• ⚠️ “Difficulty breathing, swelling of the face/lips/tongue/throat, or feeling like your throat is closing — go to the nearest hospital immediately. This could be a serious allergic reaction.”
• ⚠️ “Severe skin rash with blisters, peeling skin, or sores inside the mouth/eyes — stop the medicine and go to hospital.”
• ⚠️ “Severe diarrhoea (bloody or very watery, many times a day) with fever and stomach cramps — see your doctor urgently. This can happen even up to 2 months after you finish the course.”
• ⚠️ “Yellow colour of the eyes or skin (jaundice) — see your doctor.”
• ⚠️ “Unusual bruising or bleeding — see your doctor.”

---

Things to Avoid

• “There is no specific restriction on food — you can eat normally while taking this medicine.”
• “There is no specific restriction on alcohol, but alcohol may worsen nausea and stomach discomfort. It is best to avoid alcohol while you are unwell with an infection.”
• “Do not take any other medicines (including medicines bought from the chemist without prescription, and any Ayurvedic or herbal medicines) without telling your doctor.”

---

Storage

• Tablets: “Store at room temperature in a cool, dry place. Keep away from moisture and direct sunlight. Keep out of reach of children.”
• Reconstituted oral suspension (liquid): “Store in the fridge after the chemist adds water. If you do not have a fridge, keep it in the coolest part of your house — away from the kitchen, stove, and windows. Use within 14 days (or 10 days if you cannot keep it in a fridge during summer). Throw away any leftover liquid.”
• ℹ️ Indian hot climate note: “In summer, the liquid medicine may spoil faster if left in a hot room. Try to keep it cool. If the liquid looks or smells different from when you first got it, do not use it — get a new bottle.”

---

Duration

• “This medicine is for a specific course to treat your infection — it is NOT a long-term medicine.”
• “Your doctor will tell you how many days to take it (usually 5–14 days). Please complete the full course.”
• “Do NOT stop early even if you feel better — the infection may come back and be harder to treat next time.”
• ⚠️ “If your doctor has prescribed this for a throat infection (strep throat): you MUST complete the full 10 days even if your throat feels completely fine after 2–3 days. Stopping early can cause a serious heart problem (rheumatic fever) — this is especially important in India.”

---

Follow-Up

• “Come back to your doctor if you are not feeling better after 3 days of taking this medicine.”
• “Come back for any tests your doctor has asked for.”
• “If you had a urine infection, your doctor may ask for a repeat urine test after finishing the course to confirm the infection is gone.”
• “For throat infections: your doctor may want to recheck 2–4 weeks after treatment if you have had repeated throat infections.”

---

Common Patient Questions

---

Caregiver / Family Counselling

• ✔ How to give the correct dose — use the measuring cup or oral syringe provided, NOT a household spoon.
• ✔ Timing — twice a day, about 12 hours apart. With or without food.
• ✔ For liquid: shake well before every dose. Store in fridge. Discard after 14 days.
• ✔ If the child vomits within 30 minutes: give the same dose again. If after 30 minutes: do NOT repeat.
• ✔ Complete the full course — even if the child seems well. Especially for throat infections: 10 full days.
• ✔ Warning signs to watch for: difficulty breathing, swelling of face/lips, severe rash/blisters, severe diarrhoea, reduced urine output, excessive drowsiness. Bring to hospital immediately.
• ✔ Do NOT share this antibiotic with another family member or save leftover doses for future illness.
• ✔ If cost is a concern, ask the doctor about alternatives (see below).

---

India-Specific Adherence Support

---

BRANDS AVAILABLE IN INDIA

---

Jan Aushadhi / PMBJP Brands

---

Major Private Brands

---

PRICE RANGE (INR)

---

Per-Unit Pricing

---

Estimated Per-Course Cost

---

Cost Comparison with Key Alternatives

• First-line agents have failed or are not tolerated
• Paediatric taste compliance is a demonstrated barrier (the cost of a completed cefprozil course is better value than the cost of an incomplete cefuroxime axetil course)
• The patient specifically requires a food-independent, twice-daily oral cephalosporin with H. influenzae coverage

---

CLINICAL PEARLS

---

---

• Elderly patients with poor appetite or irregular eating
• Children who eat unpredictably
• Patients during religious fasting (Ramadan, Navratri)
• Ill patients with nausea/anorexia who cannot eat

---

---

• Both parents work and the child is at school
• Mid-day dosing is frequently missed
• Adherence drops sharply after day 3 of a TDS/QID regimen

---

---

---

VERSION

---

REFERENCES

1. CDSCO Product Insert — Cefprozil Tablets and Cefprozil Oral Suspension (multiple manufacturers; representative inserts from Sun Pharmaceutical Industries [Procef] and Glenmark Pharmaceuticals [Kezipro]). CDSCO-approved labelling for indications, dosing, contraindications, adverse effects, pharmacokinetics, renal adjustment.
2. Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission. Monograph: Cefprozil. Drug standards, identification, assay.
3. National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Referenced to confirm cefprozil is NOT NLEM-listed. Referenced for NLEM-listed alternatives (amoxicillin, amoxicillin-clavulanate, cephalexin, nitrofurantoin, penicillin V, benzathine penicillin G, azithromycin, ceftriaxone) used as comparators in this monograph.
4. National Formulary of India, 6th Edition (2021) — Indian Pharmacopoeia Commission. Cephalosporin class monograph. General dosing, adverse effects, pharmacokinetics.
5. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2019 — Indian Council of Medical Research. Guidance on empirical antibiotic selection for pharyngitis, AOM, sinusitis, CAP, AECOPD, UTI, and SSTI. Resistance data for Indian pathogens. Antimicrobial stewardship recommendations. ESBL prevalence data in Indian uropathogens.
6. API Textbook of Medicine, 11th Edition — Association of Physicians of India. Chapters on: Pharyngitis and Rheumatic Fever (including RHD burden in India), Acute Otitis Media, Acute Bacterial Sinusitis, Community-Acquired Pneumonia, COPD and AECOPD, Urinary Tract Infections, Skin and Soft Tissue Infections, Antimicrobial Stewardship.
7. IAP (Indian Academy of Pediatrics) Guidelines:
8. • IAP Guidelines on Management of Acute Otitis Media in Children (revised edition) — recommended amoxicillin first-line, cephalosporins as second-line.
   • IAP Guidelines on GAS Pharyngitis — recommended penicillin/amoxicillin first-line; cephalosporins as second-line alternative. Emphasis on 10-day course for rheumatic fever prevention.
   • IAP Guidelines on Paediatric Community-Acquired Pneumonia (revised 2021).
   • IAP Guidelines on Urinary Tract Infections in Children.
   • IAP Guidelines on Antimicrobial Stewardship in Paediatrics.
9. NNF (National Neonatology Forum of India) Clinical Practice Guidelines — Neonatal Sepsis: Diagnosis and Management (latest edition). Referenced to confirm standard neonatal sepsis regimen (ampicillin + gentamicin) and that cefprozil is NOT appropriate for neonatal infections.
10. WHO Pocket Book of Hospital Care for Children, 2nd Edition (2013) — World Health Organization. Paediatric dosing references, pneumonia and sepsis management. Referenced for context on paediatric antibiotic prescribing.
11. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (editors). Chapter: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. Pharmacology of cefprozil, mechanism of action, PK/PD of beta-lactams, spectrum of activity, cephalosporin generation classification, comparison of oral cephalosporin pharmacokinetics (bioavailability, food effects, protein binding, half-lives), cross-reactivity data between beta-lactam subclasses.
12. Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Jameson JL, Fauci AS, Kasper DL, et al. (editors). Chapters: Treatment of Bacterial Infections, Pharyngitis, Otitis Media, Sinusitis, Pneumonia, UTI, SSTI, COPD Exacerbations.
13. GOLD 2024 — Global Initiative for Chronic Obstructive Lung Disease Report — Referenced for AECOPD antibiotic indications and Anthonisen criteria for antibiotic use.
14. Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 2004; 113(4):866–882. Referenced for evidence supporting cephalosporins (including cefprozil) as second-line therapy for GAS pharyngitis with slightly higher eradication rates vs penicillin, and for evidence supporting once-daily cephalosporin dosing for GAS pharyngitis (off-label evidence basis).
15. NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) — Referenced to confirm cefprozil is NOT under NPPA price ceiling (NOT NLEM-listed). Available at nppaindia.nic.in.
16. PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue. Referenced to confirm cefprozil is NOT available through Jan Aushadhi stores. Available at janaushadhi.gov.in.
17. CDSCO Banned Drugs List — Gazette of India notifications on banned/restricted fixed-dose combinations. Reviewed to confirm no cefprozil formulation ban status.
18. PvPI (Pharmacovigilance Programme of India) — ADR reporting guidelines and mechanism. Central Drugs Standard Control Organisation. Available at cdsco.gov.in. Helpline: 1800-180-3024.
19. AIIMS Treatment Guidelines / Protocols — All India Institute of Medical Sciences, New Delhi. Referenced for: antimicrobial stewardship recommendations, empirical antibiotic selection for community-acquired infections. General support for cephalosporin class positioning.

---